Stock S1RP34 SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Sarepta Therapeutics, Inc. Sao Paulo

Equities

S1RP34

BRS1RPBDR005

Delayed Sao Paulo
Other stock markets
 17:49:53 18/06/2024 BST 		5-day change 1st Jan Change
32.37 BRL -0.28% Intraday chart for Sarepta Therapeutics, Inc. -2.44% +40.98%
06-13 Health Care Flat on Mixed Drug Developments - Health Care Roundup DJ
06-03 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The firm trades with high earnings multiples: 35.73 times its 2024 earnings per share.
  • With an enterprise value anticipated at 5.19 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+40.98% 11.11B -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+18.08% 112B
B+
ARGENX SE Stock argenx SE
+4.43% 22.57B
B
BIONTECH SE Stock BioNTech SE
-18.15% 20.82B
B+
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.13% 16.3B
B
GENMAB A/S Stock Genmab A/S
-16.61% 16.19B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-43.53% 16.17B
A-
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.19% 13.17B
C+
INSMED INCORPORATED Stock Insmed Incorporated
+108.20% 10.57B
C
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. S1RP34 Stock
  5. Ratings Sarepta Therapeutics, Inc.